Hamilton David, Batist Gerald
Sir Mortimer B Davis-Jewish General Hospital, Department of Pharmacology and Therapeutics, McGill University, Montreal, Canada.
IDrugs. 2005 Aug;8(8):662-9.
Telik Inc is developing TLK-199, an intravenous inhibitor of glutathione S-transferase P1-1, for the potential prevention of myelosuppression in blood diseases, namely myelodysplastic syndrome.
特利克公司正在研发TLK-199，一种谷胱甘肽S-转移酶P1-1的静脉内抑制剂，用于潜在预防血液疾病（即骨髓增生异常综合征）中的骨髓抑制。
